BMO Capital upgraded Ingevity (NGVT) to Outperform from Market Perform with a price target of $65, up from $62. With activist Vision One now in Ingevity, investors are “better protected from downside risks and should enjoy the coming lift” tied to the company’s improved earnings and cash flow, the analyst tells investors in a research note. The firm says that while there are still risks tied to tariffs, the presence of the activist in this “undervalued company” will provide downside protection in the stock, skewing the risk/reward positively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGVT:
- Ingevity price target raised to $62 from $61 at BMO Capital
- Ingevity’s Balanced Outlook: Growth Prospects Amid Strategic Challenges
- Ingevity Reports 2024 Financial Results Amid Strategic Shift
- Ingevity’s Earnings Call: Record Gains Amid Challenges
- Ingevity sees FY25 revenue $1.3B-$1.4B, consensus $1.45B